Christine M. Bestvina

Author

Also Known As

Alessandra Esposito, C. Bestvina, C.M. Bestvina, Christine M. Bestvina, Christine Bestvina, Christine M Bestvina, Christine M. Bestvina

261

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

University of Chicago Northwestern University The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Stanford University

About

Christine M. Bestvina is an author at University of Chicago specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	2.3K
2	Health Sciences	4	4	141
3	Cell Biology	3	3	203
4	Public Health	1	1	1.8K
5	Epidemiology	1	1	1.8K

Christine M. Bestvina

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, The Lancet EpidemiologyCancer EpidemiologyMedicineGlobal HealthEpidemiology Of Cancer	2020	1.8K
Patient-Oncologist Cost Communication, Financial Distress, and Medication Adherence Christine M. Bestvina, Leah L. Zullig, Christel Rushing, Journal of Oncology Practice	2014	255
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti, Cancer Discovery	2023	166
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study Christine M. Bestvina, Kelli B. Pointer, Theodore Karrison, Journal of Thoracic Oncology Adaptive RadiotherapyRadiation MedicineRadiation TherapyMedicineSequential Ipilimumab	2021	122
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong, Nature	2024	117
Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. Ferdinandos Skoulidis, Kathryn C. Arbour, Matthew D. Hellmann, Journal of Clinical Oncology ImmunologyPathologyFirst-line CppCancer BiologyDoublet Chemotherapy	2019	99
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer Stanley I. Gutiontov, William Tyler Turchan, Liam F. Spurr, Scientific Reports	2021	98
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade Liam F. Spurr, Carlos Alberto Martínez, Wenjun Kang, Nature Cancer Radiation OncologyCancer ImmunosurveillanceMedicineImmunologyBronchial Neoplasm	2022	89
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Nature Medicine Phase 1BOncologyGastrointestinal OncologyColorectal CancerPathology	2024	73
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC Jacobi Hines, Robert B. Cameron, A. Esposito, Journal of Thoracic Oncology	2024	62

Page 1